ClinicalTrials.gg
CompletedNCT05498233Updated Jul 27, 2023

Pharmacokinetics and Bioequivalence of Doxylamine + Pyridoxine, Film-coated, Enteric-soluble Tablets, and Diclectin, Delayed Release Tablets, in Healthy Volunteers

An interventional study of Doxylamine + Pyridoxine in Pregnancy Related and Nausea, sponsored by Valenta Pharm JSC. Completed at 1 site in Russian Federation. Open to female participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Valenta Pharm JSC · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Study summary

The study aimed for:

  1. Comparative assessment of pharmacokinetic parameters and bioequivalence of the drug Doxylamine + Pyridoxine, enteric-soluble film-coated tablets, 10 mg + 10 mg (Valenta Pharm JSC, Russia), and Diclectin, delayed-release tablets, 10 mg + 10 mg (registrant: Tzamal Bio-Pharma, Israel, manufacturer: Duchesnay Inc, Canada), in healthy volunteers in fasted conditions.
  2. Comparative evaluation of the safety of the drug Doxylamine + Pyridoxine, enteric-soluble film-coated tablets, 10 mg + 10 mg (Valenta Pharm JSK, Russia), and Diclectin, delayed-release tablets, 10 mg + 10 mg (registrant: Tzamal Bio-Pharma, Israel, manufacturer: Duchesnay Inc, Canada), based on the analysis of adverse events (AEs).
02

Conditions studied

  • Pregnancy Related
  • Nausea

Browse trials for

03

In context

Nausea

644 studies on the registry are indexed under Nausea; 85 are open to participants now.

This study's enrollment of 28 is below the median of 96 across 544 interventional studies indexed under Nausea.

Browse Nausea studies →

Lead sponsor

Valenta Pharm JSC is the lead sponsor of 40 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary and handwritten form signed by a healthy volunteer to participate in the study before any of the study procedures.
  2. Women of reproductive age (18 to 49 years inclusive, according to World Health Organization criteria).
  3. Verified diagnosis "healthy" (absence of abnormalities according to clinical, laboratory, instrumental methods of examination stipulated by the protocol).
  4. Blood pressure (BP) level: systolic blood pressure (SBP) from 100 to 139 mmHg, diastolic blood pressure (DBP) from 60 to 89 mmHg (inclusive).
  5. Heart rate (HR) from 60 to 90 bpm (inclusive).
  6. Respiratory rate (HR) from 12 to 18 bpm (inclusive).
  7. Body temperature of 36 to 36.9°C (inclusive).
  8. (BMI) is 18.5 ≤ BMI ≤ 30 kg/m2, and the body weight must be ≥ 45 kg.
  9. Consent to use adequate methods of throughout the study and for 30 days after completion, negative pregnancy test.
  10. Volunteers must behave adequately, coherent speech must be observed.

Exclusion criteria

Exclusion Criteria:

  1. A history of allergic reactions.
  2. Drug intolerance of active and/or included in the study drugs in the anamnesis.
  3. Chronic diseases of the cardiovascular, lymphatic, respiratory, nervous, endocrine, digestive, musculoskeletal, covering, immune systems, as well as of the urogenital system and hematopoietic organs.
  4. Values of standard laboratory and instrumental indices beyond the limits of local laboratory norms.
  5. History of gastrointestinal surgery (except appendectomy at least 1 year before screening).
  6. Diseases/conditions that the investigator believes may affect the absorption, distribution, metabolism, or excretion of the study medication.
  7. Acute infectious disease less than 4 weeks prior to screening.
  8. Taking drugs that have a significant effect on hemodynamics and drugs that affect liver function (barbiturates, benzodiazepines, omeprazole, cimetidine, etc.) for less than one month before screening.
  9. Regular intake of drugs less than 2 weeks before screening and one-time intake of drugs less than 7 days before screening.
  10. Donating blood or plasma less than 3 months before the screening visit.
  11. Use of hormonal less than 2 months before the screening visit.
  12. Using depot injections of any medications less than 3 months prior to the screening visit.
  13. Pregnancy or lactation, positive pregnancy test.
  14. Participation in another clinical trial less than 3 months before screening or concurrently with this study.
  15. Taking more than 10 units of alcohol (1 unit of alcohol is equivalent to 330 ml of beer, 150 ml of wine, or 40 ml of spirits) in the week in the last month before inclusion in the study or anamnestic evidence of alcoholism, drug abuse, or medicine abuse.
  16. Smoking.
  17. Positive blood tests for antibodies to (HIV) type 1 and 2, antibodies to Treponema pallidum antigens, surface antigen (HBsAg), antibodies to virus antigens, laboratory examination of biomaterial (nasopharyngeal swab) for SARS-Cov-2 RNA (COVID-19).
  18. abnormalities on (ECG).
  19. Positive urinalysis for narcotics and powerful drugs.
  20. Positive breath alcohol vapor test.
  21. Scheduling an inpatient stay during the study period, for any reason other than hospitalization required by this protocol.
  22. Failure or inability to comply with protocol requirements, perform protocol-prescribed procedures, diet, and activity regimen.
  23. Observance of a religious fast or special diet (e.g., vegetarian, vegan).
  24. Other conditions that, in the opinion of the Investigator, preclude a volunteer from enrolling in the study or may result in early withdrawal from the study, including special lifestyles (night work, extreme physical activity).

Withdrawal criteria:

  1. The volunteer's refusal to further participate in the study.
  2. Failure of the volunteer to comply with the rules of participation in the study (skipping study procedures, independent use of drugs prohibited in the study, violation of dietary and lifestyle restrictions, etc.).
  3. Occurrence of causes/occurrence during the study of situations that threaten the safety of the volunteer (e.g., reactions, etc.).
  4. Volunteers included in the study in violation of the inclusion/inclusion criteria.
  5. Development of a severe and/or serious adverse event (AE) in a volunteer during the study.
  6. Missing 2 or more consecutive blood samples or 3 or more blood samples during one Period of the pharmacokinetic portion of the study.
  7. Occurrence of vomiting/diarrhea within 24 h of study drug administration (the choice of time interval is based on the tmax parameter value for doxylamine and pyridoxal-5-phosphate not exceeding 7.2 ± 1.9 and 11.7 ± 5.3 h, respectively, according to the manufacturer of the reference drug).
  8. Positive urine test for narcotic substances and potent drugs.
  9. Positive breath alcohol vapor test.
  10. A positive pregnancy test.
  11. Positive test for SARS-Cov-2 RNA (COVID-19);
  12. Other causes occurring in the course of the study that prevent the study from being conducted according to the protocol.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Other
    RT-sequence

    Group 1 (14 volunteers, RT sequence) will take 2 tablets of Diclectin in Period 1 and 2 tablets of Doxylamine + Pyridoxine in Period 2

    Drug: Doxylamine + Pyridoxine

  • Other
    TR-sequence

    Group 2 (14 volunteers, sequence TR) will take 2 tablets of Doxylamine + Pyridoxine in Period 1 and 2 tablets of Diclectin in Period 2.

    Drug: Doxylamine + Pyridoxine

Interventions

  • DrugDoxylamine + Pyridoxine

    Drug pages: Doxylamine · Pyridoxine

    A single dose of R or T drug in each of 2 periods of the study in fasted conditions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics - Cmax (Doxylamine)

    Maximum plasma concentration (Cmax)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  2. Pharmacokinetics - Cmax (Pyridoxal-5-phosphate)

    Maximum plasma concentration (Cmax)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  3. Pharmacokinetics - tmax (Doxylamine)

    Time to reach Cmax (tmax)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  4. Pharmacokinetics - tmax (Pyridoxal-5-phosphate)

    Time to reach Cmax (tmax)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  5. Pharmacokinetics - AUC0-t (Doxylamine)

    Area under the plasma concentration-time curve from time 0 to t (AUC0-t)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  6. Pharmacokinetics - AUC0-t (Pyridoxal-5-phosphate)

    Area under the plasma concentration-time curve from time 0 to t (AUC0-t)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  7. Pharmacokinetics - AUC0-inf (Doxylamine)

    Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  8. Pharmacokinetics - AUC0-inf (Pyridoxal-5-phosphate)

    Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  9. Pharmacokinetics - AUCextr (Doxylamine)

    Extrapolated AUC, defined as (AUC0-inf - AUC0-t)/AUC0-inf

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  10. Pharmacokinetics - AUCextr (Pyridoxal-5-phosphate)

    Extrapolated AUC, defined as (AUC0-inf - AUC0-t)/AUC0-inf

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  11. Pharmacokinetics - t1/2 (Doxylamine)

    Elimination half-life (t1/2)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  12. Pharmacokinetics - t1/2 (Pyridoxal-5-phosphate)

    Elimination half-life (t1/2)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  13. Pharmacokinetics - kel (Doxylamine)

    Elimination constant (kel)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  14. Pharmacokinetics - kel (Pyridoxal-5-phosphate)

    Elimination constant (kel)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  15. Pharmacokinetics - MRT (Doxylamine)

    Mean residence time (MRT)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  16. Pharmacokinetics - MRT (Pyridoxal-5-phosphate)

    Mean residence time (MRT)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  17. Bioequivalence - ratio of Cmax (Doxylamine)

    Ratio of geometric mean Cmax after intake of R or T (with 90% confidence intervals)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  18. Bioequivalence - ratio of Cmax (Pyridoxal-5-phosphate)

    Ratio of geometric mean Cmax after intake of R or T (with 90% confidence intervals)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  19. Bioequivalence - ratio of AUC0-t (Doxylamine)

    Ratio of geometric mean AUC0-t after intake of R or T (with 90% confidence intervals)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  20. Bioequivalence - ratio of AUC0-t (Pyridoxal-5-phosphate)

    Ratio of geometric mean AUC0-t after intake of R or T (with 90% confidence intervals)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  21. Bioequivalence - ratio of AUC0-inf (Doxylamine)

    Ratio of geometric mean AUC0-inf after intake of R or T (with 90% confidence intervals)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

  22. Bioequivalence - ratio of AUC0-inf (Pyridoxal-5-phosphate)

    Ratio of geometric mean AUC0-inf after intake of R or T (with 90% confidence intervals)

    Time frame: From 0 to 72 hours (Day 1-4 and Day 22-25)

Secondary outcomes

  1. Safety and Tolerability: adverse event (AE) number and frequency

    Number and frequency of adverse events (AEs)

    Time frame: From the screening (and signing informed consent form) to Day 29 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 29)

  2. serious adverse event (SAE) number and frequency

    Number and frequency of serious AEs (SAEs)

    Time frame: From the screening (and signing informed consent form) to Day 29 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 29)

  3. Safety and Tolerability: vital signs - systolic blood pressure (SBP)

    SBP, mmHg

    Time frame: Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  4. Safety and Tolerability: vital signs - diastolic blood pressure (DBP)

    DBP, mmHg

    Time frame: Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  5. Safety and Tolerability: vital signs - respiratory rate (RR)

    RR, breaths per minute

    Time frame: Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  6. Safety and Tolerability: vital signs - heart rate (HR)

    HR, beats per minute

    Time frame: Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  7. Safety and Tolerability: vital signs - body temperature

    Body temperature, centigrade scale

    Time frame: Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  8. Safety and Tolerability: physical examination results

    Physical examination will follow the general rules of internal medicine: general examination, examination of mucous membranes and skin, including palpation of lymph nodes, evaluation of the musculoskeletal system, palpation, percussion, and auscultation of the main organ systems (cardiovascular, respiratory, digestive, and urinary systems) will be performed sequentially.

    Time frame: Screening, from Day 0 to Day 4, from Day 21 to Day 25, and/or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  9. Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate

    12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: heart rate (beats per minute)

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  10. Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval

    12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: PQ interval (ms)

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  11. Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex

    12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QRS complex (ms)

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  12. Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval (QTc)

    12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QTc (ms)

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  13. Safety and Tolerability: urinalysis - color

    Color of the urine

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  14. Safety and Tolerability: urinalysis - transparency

    Transparency of the urine

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  15. Safety and Tolerability: urinalysis - pH

    pH of the urine

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  16. Safety and Tolerability: urinalysis - specific gravity

    Specific gravity of the urine

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  17. Safety and Tolerability: urinalysis - protein

    Protein in the urine (g/L)

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  18. Safety and Tolerability: urinalysis - glucose

    Glucose in the urine (mmol/L)

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  19. Safety and Tolerability: urinalysis (microscopy) - red blood cells

    Red blood cells in the urine (number in sight)

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  20. Safety and Tolerability: urinalysis (microscopy) - white blood cells

    White blood cells in the urine (number in sight)

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  21. Safety and Tolerability: urinalysis (microscopy) - epithelial cells

    Epithelial cells in the urine (number in sight)

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  22. Safety and Tolerability: urinalysis (microscopy) - cylinders

    Cylinders in the urine (number in sight)

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  23. Safety and Tolerability: urinalysis (microscopy) - mucus

    Mucus in the urine (presence in sight)

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  24. Safety and Tolerability: urinalysis (microscopy) - bacteria

    Bacteria in the urine (number in sight)

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  25. Safety and Tolerability: complete blood count - hemoglobin

    Hemoglobin, g/dL

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  26. Safety and Tolerability: complete blood count - red blood cells

    Red blood cells, 10\^6/uL

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  27. Safety and Tolerability: complete blood count - hematocrit

    Hematocrit, %

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  28. Safety and Tolerability: complete blood count - platelets

    Platelets, 10\^3/uL

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  29. Safety and Tolerability: complete blood count - white blood cells

    White blood cells, 10\^3/uL

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  30. Safety and Tolerability: complete blood count - erythrocyte sedimentation rate

    Erythrocyte sedimentation rate, mm per hour

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  31. Safety and Tolerability: complete blood count - neutrophils

    Neutrophils, %

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  32. Safety and Tolerability: complete blood count - lymphocytes

    Lymphocytes, %

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  33. Safety and Tolerability: complete blood count - eosinophils

    Eosinophils, %

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  34. Safety and Tolerability: complete blood count - monocytes

    Monocytes, %

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  35. Safety and Tolerability: complete blood count - basophils

    Basophils, %

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  36. Safety and Tolerability: blood test results - total protein

    Total protein in blood serum, g/L

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  37. Safety and Tolerability: blood test results - creatinine

    Creatinine in blood serum, umol/L

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  38. Safety and Tolerability: blood test results - glucose

    Glucose in blood serum, mmol/L

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  39. Safety and Tolerability: blood test results - total bilirubin

    Total bilirubin in blood serum, umol/L

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  40. Safety and Tolerability: blood test results - total cholesterol

    Total cholesterol in blood serum, mmol/L

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  41. Safety and Tolerability: blood test results - alanine transaminase (ALT)

    ALT in blood serum, U/L

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  42. Safety and Tolerability: blood test results - aspartate transaminase (AST)

    AST in blood serum, U/L

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

  43. Safety and Tolerability: blood test results - alkaline phosphatase (ALP)

    ALP in blood serum, U/L

    Time frame: Screening, Day 4, Day 25 or on early termination visit within the time frame of the study (from Day 0 to Day 29)

07

Study locations

1 site
  • Llc "Certa Clinic"
    Moscow, Russian Federation
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Sep 2022, 1 month.

Of 126 interventional studies with no phase under Nausea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2022
First posted
Aug 12, 2022
StartActual
Aug 18, 2022
Primary completionActual
Sep 19, 2022
CompletionActual
Sep 19, 2022
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05498233
Lead sponsor
Valenta Pharm JSC
Responsible party
Sponsor
First posted
Aug 12, 2022
Start date
Aug 18, 2022
Primary completion
Sep 19, 2022
Completion
Sep 19, 2022
Last update
Jul 27, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doxylamine · Pyridoxine

Start the discussion